{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:51:02Z","timestamp":1778939462344,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T00:00:00Z","timestamp":1694217600000},"content-version":"am","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ygyno.2022.06.022","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T23:45:45Z","timestamp":1658792745000},"page":"389-396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study"],"prefix":"10.1016","volume":"166","author":[{"given":"Florence","family":"Joly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Fabbro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Berton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Lequesne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00e9lie","family":"Anota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicja","family":"Puszkiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Floquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Vegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugues","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le\u00efla","family":"Bengrine Lefevre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beno\u00eet","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Pommeret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Spaeth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Claire","family":"Hardy-Bessard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyril","family":"Abdeddaim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Christine","family":"Kaminsky-Forrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Tod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Emmanuel","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Del Piano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Meunier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Raban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9rome","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Ange","family":"Mouret-Reynier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Provansal Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Emmanuel","family":"Brachet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.ygyno.2022.06.022_bb0005","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ygyno.2022.06.022_bb0010","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"ICON7 investigators. A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.ygyno.2022.06.022_bb0015","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"PAOLA-1 investigators. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.ygyno.2022.06.022_bb0020","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2022.06.022_bb0025","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2022.06.022_bb0030","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1470-2045(20)30142-X","article-title":"AGO-OVAR 2.21\/ENGOT-ov 18 investigators. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial","volume":"21","author":"Pfisterer","year":"2020","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2022.06.022_bb0035","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.06.022_bb0040","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(20)30637-9","article-title":"MITO16b\/MANGO\u2013OV2\/ENGOT\u2013ov17 investigators. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial","volume":"22","author":"Pignata","year":"2021","journal-title":"Lancet Oncol."},{"issue":"30","key":"10.1016\/j.ygyno.2022.06.022_bb0045","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.06.022_bb0050","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdx796","volume":"29","author":"Friedlander","year":"2018","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.06.022_bb0055","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdr149","article-title":"Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des cancers Ovariens (GINECO)","volume":"23","author":"Lortholary","year":"2012","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.06.022_bb0060","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ygyno.2022.01.015","article-title":"BAROCCO study group. Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer","volume":"164","author":"Colombo","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.06.022_bb0065","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ygyno.2018.12.008","article-title":"A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: an NRG Oncology\/Gynecologic Oncology Group study","volume":"152","author":"Matulonis","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.06.022_bb0070","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ygyno.2018.01.019","article-title":"Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer","volume":"149","author":"Oza","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2022.06.022_bb0075","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrclinonc.2010.120","article-title":"Weekly paclitaxel in the treatment of recurrent ovarian cancer","volume":"7","author":"Baird","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"32","key":"10.1016\/j.ygyno.2022.06.022_bb0080","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2022.06.022_bb0085","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","article-title":"MITO 11 investigators. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial","volume":"16","author":"Pignata","year":"2015","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.06.022_bb0090","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jamaoncol.2017.4218","article-title":"Paclitaxel with and without pazopanib for persistent or recurrent ovarian cancer: a randomized clinical trial","volume":"4","author":"Richardson","year":"2018","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.06.022_bb0095","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"15 Suppl","key":"10.1016\/j.ygyno.2022.06.022_bb0100","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1200\/JCO.2019.37.15_suppl.5512","article-title":"Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: the CHIVA double-blind randomized phase II GINECO study","volume":"37","author":"Ferron","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2022.06.022_bb0105","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s40262-017-0510-z","article-title":"Clinical pharmacokinetics and pharmacodynamics of pazopanib: towards optimized dosing","volume":"56","author":"Verheijen","year":"2017","journal-title":"Clin. Pharmacokinet."},{"issue":"11","key":"10.1016\/j.ygyno.2022.06.022_bb0110","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1002\/ijc.33469","article-title":"The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure","volume":"148","author":"Krens","year":"2021","journal-title":"Int. J. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822004267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822004267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:02:22Z","timestamp":1758772942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822004267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0090825822004267"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.06.022","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}